TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23404659

Group type: EXPERIMENTAL
Intervention: Family intervention (Focus on Families project)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 151
Study: 22972960

Group type: EXPERIMENTAL
Intervention: Proprioceptive training with visual demonstration and robotic assistance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual demonstration alone (Control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Proprioceptive guidance during active movement (Additional Control)
Number of subjects: 0
Study: 20410466

Group type: EXPERIMENTAL
Intervention: Therapy-based oncology RCTs
Number of subjects: 262
Study: 17645811

Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nitrendipine
Number of subjects: 0
Study: 16162039

Group type: EXPERIMENTAL
Intervention: Tailored dissemination materials plus 2 brief follow‐up phone calls (tailored group)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Generic materials (basic group)
Number of subjects: 126
Study: 11575897

Group type: EXPERIMENTAL
Intervention: Formoterol (Oxis Turbuhaler 4.5 microg)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Terbutaline (Bricanyl Turbuhaler 0.5 mg)
Number of subjects: 362
Study: 9272401

Group type: EXPERIMENTAL
Intervention: Yohimbine (3 x 6 mg per day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Anetholtrithione (3 x 25 mg per day)
Number of subjects: 10
Study: 7942085

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) with estradiol and estradiol plus medroxyprogesterone acetate
Number of subjects: 15

Group type: COMPARATOR
Intervention: Amenorrheic patients
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normally cycling women (control group)
Number of subjects: 15
Study: 3367488

Group type: EXPERIMENTAL
Intervention: Cendehill rubella virus vaccine
Number of subjects: 1290

Group type: EXPERIMENTAL
Intervention: HPV‐77 DE‐5 rubella virus vaccine
Number of subjects: 1290

Group type: EXPERIMENTAL
Intervention: HPV‐77 DK‐12 rubella virus vaccine
Number of subjects: 1290
Study: 1957903

Group type: EXPERIMENTAL
Intervention: betaxolol 0.5%
Number of subjects: 40

Group type: COMPARATOR
Intervention: timolol 0.5%
Number of subjects: 40
Study: 56908

Group type: EXPERIMENTAL
Intervention: Epontol (7 mg/kg i.v.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined injection of Epontol (7 mg/kg) and infusion (21 mg/kg during 15 min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined injection of Epontol (7 mg/kg) and suxamethonium (0.5 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anaesthesia with ketamine (Ketanest), halothane or nitrous oxide
Number of subjects: 0
Study: 31987540

Group type: EXPERIMENTAL
Intervention: True Qigong
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sham Qigong (Control)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Waiting list group
Number of subjects: 66
Study: 31893588

Group type: EXPERIMENTAL
Intervention: Air-infused vitrectomy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (traditional balanced salt solution-infused technique)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study: 28099193

Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Stimulation (PNS)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Physical Therapy (PT)
Number of subjects: 25
Study: 25365122

Group type: EXPERIMENTAL
Intervention: Mindfulness-Enhanced Strengthening Families Program (MSFP)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Standard Strengthening Families Program (SFP 10-14)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Minimal-treatment home study control condition
Number of subjects: 432
Study: 23057434

Group type: EXPERIMENTAL
Intervention: Milk (5 mL)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Glucose (25% glucose water, 5 mL)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Water (5 mL distilled water)
Number of subjects: 123
Study: 21665265

Group type: COMPARATOR
Intervention: Heparin plus a glycoprotein IIb/IIIa inhibitor (GPI)
Number of subjects: 1802

Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy
Number of subjects: 1802

Group type: COMPARATOR
Intervention: Bare-metal stent
Number of subjects: 1802

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent
Number of subjects: 1802
Study: 19659617

Group type: EXPERIMENTAL
Intervention: Pulmonary vein antrum isolation (PVAI) with therapeutic INR (mean INR 2.8 +/- 0.7)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Normal INR (mean INR 1.4 +/- 0.3)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Combined endpoint of major and minor complications
Number of subjects: 194
Study: 16912354

Group type: EXPERIMENTAL
Intervention: Subcutaneous extralesional triamcinolone acetonide injection (0.3 mL, 10 mg/mL)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conservative treatment (lid hygiene, warm compresses, chloramphenicol 1% ointment 4 times a day)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Subcutaneous extralesional triamcinolone acetonide injection
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 28
Study: 14755153

Group type: EXPERIMENTAL
Intervention: Probiotics in capsules
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Probiotics in liquid form
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo in both forms
Number of subjects: 35
Study: 11985972

Group type: EXPERIMENTAL
Intervention: Prophylaxis group (2 g of cephtazidime intravenously 30 minutes before ERCP)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 321
Study: 9271042

Group type: EXPERIMENTAL
Intervention: DTPa-IPV vaccine
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: DTPa-IPV and Hib vaccine (mixed)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: DTPa-IPV and Hib vaccine (separate)
Number of subjects: 145

Group type: COMPARATOR
Intervention: DTPw-IPV-Hib vaccine
Number of subjects: 145
Study: 7935634

Group type: COMPARATOR
Intervention: Immediate fluid resuscitation
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Delayed fluid resuscitation
Number of subjects: 598
Study: 3366075

Group type: EXPERIMENTAL
Intervention: Intravenous fenoterol (bolus injection and continuous infusion)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intravenous fenoterol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Simultaneous and continuous intravenous administration of fenoterol and theophylline
Number of subjects: 8
Study: 30158215

Group type: EXPERIMENTAL
Intervention: 3D intervention
Number of subjects: 5253

Group type: COMPARATOR
Intervention: Usual primary care
Number of subjects: 5253
Study: 27862464

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Imatinib 800 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Functional independence (mRS 0-2) with Imatinib
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 25053749

Group type: EXPERIMENTAL
Intervention: FroDex25 (frovatriptan 2.5 mg + dexketoprofen 25 mg)
Number of subjects: 76
Study: 23566639

Group type: EXPERIMENTAL
Intervention: P/MC (sodium picosulfate and magnesium citrate)
Number of subjects: 601

Group type: COMPARATOR
Intervention: 2L PEG‐3350 and bisacodyl tablets
Number of subjects: 601
Study: 21447908

Group type: EXPERIMENTAL
Intervention: Supervised exercise training program twice a week for 6 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 28
Study: 19428097

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (FFNS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16455424

Group type: EXPERIMENTAL
Intervention: 3-dimensional echocardiography (3DE)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TI-201 single photon emission computed tomography (SPECT)
Number of subjects: 30
Study: 15381675

Group type: EXPERIMENTAL
Intervention: L-NAME (66 microg/kg per min for 30 minutes)
Number of subjects: 10

Group type: COMPARATOR
Intervention: L-arginine (3 g TID) plus ramipril (10 mg QD)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: L-NAME
Number of subjects: 10

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 10
Study: 11528242

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 40 mg of iron during the first ten HD sessions (n = 12)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Weekly injection of 40 mg of iron for 10 weeks (n = 12)
Number of subjects: 35

Group type: COMPARATOR
Intervention: No iron supplementation (n = 11)
Number of subjects: 35
Study: 9623154

Group type: EXPERIMENTAL
Intervention: Inhalation of sodium cromoglycate through a spacer device
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study: 7940732

Group type: EXPERIMENTAL
Intervention: OKT3-based immunoprophylaxis with steroids and azathioprine for 14 days, cyclosporine introduced on day 11 posttransplant.
Number of subjects: 96

Group type: COMPARATOR
Intervention: Cyclosporine-based immunoprophylaxis with steroids and azathioprine.
Number of subjects: 96
Study: 3349748

Group type: EXPERIMENTAL
Intervention: Procan SR 1 g
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pronestyl-SR 1 g
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Procan SR and Pronestyl-SR
Number of subjects: 10
Study: 30910541

Group type: EXPERIMENTAL
Intervention: Busulfan plus melphalan
Number of subjects: 202

Group type: COMPARATOR
Intervention: Melphalan alone
Number of subjects: 202
Study: 28801399

Group type: EXPERIMENTAL
Intervention: Standard medical care plus computer-based screening and personalised assessment feedback
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard care plus computer-based sham
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study: 25743733

Group type: EXPERIMENTAL
Intervention: Oral care with an aroma solution
Number of subjects: 61

Group type: COMPARATOR
Intervention: 0.9% saline solution (Control)
Number of subjects: 61
Study: 23786836

Group type: EXPERIMENTAL
Intervention: Obese patients (BMI>30 kg/m2)
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Overweight patients (25<BMI<30 kg/m2)
Number of subjects: 730

Group type: COMPARATOR
Intervention: Patients with BMI<25 kg/m2
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Obese patients
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: Obese and overweight patients
Number of subjects: 730
Study: 22131238

Group type: EXPERIMENTAL
Intervention: Oral nifedipine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous hydralazine
Number of subjects: 50
Study: 19288431

Group type: EXPERIMENTAL
Intervention: Offer of a social counselling service
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Offer of a work-related stress coping training
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Intensity of therapy increased from 3 to 5 hours
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Reduced waiting time
Number of subjects: 223
Study: 17323586

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 20 mg
Number of subjects: 0
Study: 15565999

Group type: EXPERIMENTAL
Intervention: BID group (0.5 g morning and evening)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: TID group (0.25 g in the morning and about midday, and 0.5 g in the evening)
Number of subjects: 55
Study: 11203833

Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose (SBMP) with pre-cure technique
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond (CFLB) with pre-cure technique
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Scotchbond One‐Step (SB1S) with pre-cure technique
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: GC Fuji Bond LC with co-cure technique
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: CFLB with co-cure technique
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: CFLB with pre-cure technique
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose, Scotchbond One‐Step, Fuji Bond LC with co-cure technique
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond with pre-cure technique
Number of subjects: 90

Group type: COMPARATOR
Intervention: Negative control (no dentin bonding)
Number of subjects: 90
Study: 9093207

Group type: EXPERIMENTAL
Intervention: Tamoxifen citrate plus T undecanoate
Number of subjects: 80

Group type: COMPARATOR
Intervention: Tamoxifen citrate
Number of subjects: 80

Group type: COMPARATOR
Intervention: T undecanoate
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: T undecanoate plus tamoxifen citrate
Number of subjects: 80
Study: 1389661

Group type: EXPERIMENTAL
Intervention: iohexol with NaCl (28 mmol/l)
Number of subjects: 75

Group type: COMPARATOR
Intervention: iohexol without NaCl
Number of subjects: 75
Study: 3877280

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 60
Study: 30397257

Group type: EXPERIMENTAL
Intervention: Dietary counseling biannually from age 7 months to 20 years
Number of subjects: 1062
Study: 30098162

Group type: EXPERIMENTAL
Intervention: Medical or surgical treatment of the study eye (SE)
Number of subjects: 607
Study: 26409751

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 104

Group type: COMPARATOR
Intervention: Counseling without buprenorphine
Number of subjects: 104
Study: 23736314

Group type: COMPARATOR
Intervention: 0 mg oral naltrexone (NTX)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 12.5 mg oral naltrexone (NTX)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 50 mg oral naltrexone (NTX)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg oral D-amphetamine (D-AMPH)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 20 mg oral D-amphetamine (D-AMPH)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0 mg smoked cocaine (COC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 12.5 mg smoked cocaine (COC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 25 mg smoked cocaine (COC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 50 mg smoked cocaine (COC)
Number of subjects: 12
Study: 21871685

Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment (Group A)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional insulin treatment (Group B)
Number of subjects: 42
Study: 18978638

Group type: EXPERIMENTAL
Intervention: ERr 731
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo (initially) then ERr 731
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: All women (ERr 731 and placebo)
Number of subjects: 109
Study: 17098309

Group type: EXPERIMENTAL
Intervention: Intravenous boluses of quinaprilat
Number of subjects: 23

Group type: COMPARATOR
Intervention: Intravenous infusion of sodium nitroprusside
Number of subjects: 23
Study: 15184205

Group type: EXPERIMENTAL
Intervention: PEF plus symptom‐based management
Number of subjects: 90

Group type: COMPARATOR
Intervention: Symptom‐based management alone
Number of subjects: 90
Study: 11578760

Group type: EXPERIMENTAL
Intervention: D002 (50 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 9821900

Group type: EXPERIMENTAL
Intervention: Alternating current at 1kHz
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Alternating current at increasing frequencies (2kHz to 15kHz)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Alternating current at varying stimulus intensity
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Alternating current at 10kHz
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Alternating current at 1kHz or less
Number of subjects: 15
Study: 10384427

Group type: EXPERIMENTAL
Intervention: Java-based data collection system
Number of subjects: 0

Group type: COMPARATOR
Intervention: HTML/CGI approach
Number of subjects: 0
Study: 1859509

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 60 mg amitriptylinoxide
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral administration of 60 mg amitriptylinoxide
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Urine analysis for metabolites
Number of subjects: 12

Group type: COMPARATOR
Intervention: Overall tolerability of both preparations
Number of subjects: 12
Study: 6135365

Group type: EXPERIMENTAL
Intervention: Intervention group receiving encouragement to lower alcohol consumption and GGT measurements as biofeedback.
Number of subjects: 585

Group type: COMPARATOR
Intervention: Control group informed to be restrictive with alcohol consumption and receive new invitations for liver enzyme measurements.
Number of subjects: 585
Study: 30130424

Group type: EXPERIMENTAL
Intervention: 60 Seconds to Survival© (60S), a disaster triage screen-based simulation (SBS)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (not exposed to 60S)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Previous immersive simulation study
Number of subjects: 39
Study: 29608793

Group type: EXPERIMENTAL
Intervention: Free-handed (FH) surgery
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Pilot-drill guided (PG) surgery
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fully guided (FG) surgery
Number of subjects: 32
Study: 26095052

Group type: EXPERIMENTAL
Intervention: Ultrasound arm (annual transvaginal ultrasound examinations)
Number of subjects: 48230

Group type: EXPERIMENTAL
Intervention: Sonographers (78 included in the model)
Number of subjects: 48230

Group type: EXPERIMENTAL
Intervention: Centers (13 centers included)
Number of subjects: 48230

Group type: EXPERIMENTAL
Intervention: Sonographers over time
Number of subjects: 48230

Group type: EXPERIMENTAL
Intervention: Centers over time
Number of subjects: 48230
Study: 24225379

Group type: EXPERIMENTAL
Intervention: Fluocortolone (FC) 1 mg/kg for 5 days, followed by stepwise dose reduction
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pentoxifylline (PFX) intravenously and per os for 7 days, then per os for 6 months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluocortolone (FC) for patients with baseline BCVA >=0.05
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pentoxifylline (PFX)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluocortolone (FC)
Number of subjects: 60
Study: 21952668

Group type: COMPARATOR
Intervention: MDMA 0 mg (placebo)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: MDMA 25 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: MDMA 50 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: MDMA 100 mg
Number of subjects: 16
Study: 20651093

Group type: EXPERIMENTAL
Intervention: Somatosensory stimuli (warming and cooling temperature, pain, touch, two-point discrimination) applied to the upper lip and chin
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Taste stimuli
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Somatosensory stimuli
Number of subjects: 178
Study: 18928339

Group type: EXPERIMENTAL
Intervention: Aripiprazole (2-15 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15972695

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12432317

Group type: EXPERIMENTAL
Intervention: Early enteral feeding (within 24 hours of injury)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Delayed enteral feeding (at least 48 hours postburn)
Number of subjects: 77
Study: 9534648

Group type: EXPERIMENTAL
Intervention: Self-chosen music
Number of subjects: 12

Group type: COMPARATOR
Intervention: Silence
Number of subjects: 12

Group type: COMPARATOR
Intervention: White noise
Number of subjects: 12

Group type: COMPARATOR
Intervention: Classical music
Number of subjects: 12
Study: 9480136

Group type: EXPERIMENTAL
Intervention: Solvent/detergent-inactivated plasma (SDP-TNBT/Triton X-100)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Untreated fresh-frozen plasma (FFP)
Number of subjects: 14
Study: 3140150

Group type: EXPERIMENTAL
Intervention: Veralipride (100 mg/day for 30 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Naloxone infusion (N = 5) after Veralipride administration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 4826687

Group type: EXPERIMENTAL
Intervention: Training on a bicycle ergometer for 10 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: 5 weeks of detraining
Number of subjects: 44

Group type: COMPARATOR
Intervention: 10 weeks of detraining
Number of subjects: 44
Study: 29893223

Group type: EXPERIMENTAL
Intervention: Hip arthroscopy
Number of subjects: 348

Group type: COMPARATOR
Intervention: Personalised hip therapy
Number of subjects: 348
Study: 28814431

Group type: EXPERIMENTAL
Intervention: Calprotectin
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Calprotectin after 12 months of treatment
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Baseline levels of calprotectin, ESR, and CRP
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: High levels of calprotectin
Number of subjects: 215
Study: 24566599

Group type: EXPERIMENTAL
Intervention: ceftaroline fosamil
Number of subjects: 614

Group type: COMPARATOR
Intervention: ceftriaxone
Number of subjects: 614
Study: 23182993

Group type: COMPARATOR
Intervention: Induction cisplatin/fluorouracil (PF) followed by RT
Number of subjects: 520

Group type: COMPARATOR
Intervention: Concomitant cisplatin/RT
Number of subjects: 520
Study: 20569725

Group type: EXPERIMENTAL
Intervention: Vernakalant (3 mg/kg intravenous infusion for 10 minutes, followed by 2 mg/kg if needed)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Vernakalant
Number of subjects: 236
Study: 17996926

Group type: COMPARATOR
Intervention: Pelvic radiotherapy (PRT)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide‐doxorubicin‐cisplatin (CAP) chemotherapy
Number of subjects: 385
Study: 16885205

Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy
Number of subjects: 85
Study: 12657584

Group type: EXPERIMENTAL
Intervention: Progressive addition lenses (PALs) with a +2.00 addition (n = 235)
Number of subjects: 469

Group type: COMPARATOR
Intervention: Single vision lenses (SVLs) (n = 234)
Number of subjects: 469
Study: 10826516

Group type: EXPERIMENTAL
Intervention: NN304 [0.3 U/kg]
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NN304 [0.6 U/kg]
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NPH [0.3 IU/kg]
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NPH [0.6 IU/kg]
Number of subjects: 10